This is a two part series. Part 1 covers PTSD and treatment resistant depression, the two indications with the most active regulatory pathways for MDMA and psilocybin worldwide. Part 2 will cover substance use disorder, where ibogaine is the primary tool and the regulatory map looks entirely different.
Today, somewhere in the world, someone is being treated for PTSD and depression with MDMA or psilocybin. The question for an operator is simple: where to open a clinic, and with what.
We answer it with two parameters: 1. Access speed: how fast you can legally treat your first patient. 2. Revenue speed: how fast that turns into a working clinic that gets paid. They do not move together. A country can hand you fast access and a slow business, or the reverse. Access here means a clinician's ability to legally treat PTSD or depression as a diagnosed medical condition, not a personal or wellness use carve-out. That distinction rules a few popular destinations out of contention, and it changes the ranking.
Most of the markets below run on some version of compassionate access, sometimes called compassionate use. This is a standard regulatory mechanism, not unique to psychedelics, that lets a patient use a drug still working through formal approval, when the standard treatments have failed and the patient cannot wait for or qualify for a clinical trial. The drug itself stays officially unapproved. What changes is that a specific patient, or in some countries a specific authorized clinician, gets legal permission to use it anyway.
You'll notice that two patterns emerge across these markets. In some countries (Switzerland, Canada, Israel), the regulator approves each patient individually. In others (Australia, New Zealand, Germany), the regulator clears the psychiatrist once, and the psychiatrist decides which patients to treat from there. The first is slower to run. The second is slower to start.
Switzerland
Switzerland treats more patients than anywhere else, but psilocybin and MDMA are not approved drugs there. There is no law declaring them safe and effective medicines. Instead, since 2014, individual physicians can apply to the federal health office for a one-off exceptional permission to treat one named patient. Approve enough of those one-off requests and you get a functioning treatment system, but the underlying legal status of the drugs themselves never changes. In 2024, regulators granted just under 700 of these case-by-case authorizations, psilocybin alone accounting for 322. No other country treats this many patients through a legal medical pathway. The catch is on the payment side. Switzerland requires every resident to carry basic health insurance, but that mandatory coverage does not automatically include this treatment, so many patients pay out of pocket unless their specific case is separately approved for reimbursement. For an operator, that means real patients once you are licensed and approved, but you build your own pricing and billing model rather than plugging into one the health system already runs.
Bottleneck: every individual patient needs a one-off federal sign-off, and insurance reimbursement is not automatic.
Fast access: 8/10.
Time to revenue: 7/10.
Australia
Australia has the cleanest law on paper. In 2023, regulators reclassified psilocybin and MDMA so any authorized psychiatrist can prescribe them for treatment resistant depression and PTSD specifically, a formal scheduling change rather than a case-by-case exception. The trade-off shows up in how few patients have actually moved through it so far. Fewer than 100 patients were treated in the program's first eighteen months. The bottleneck is not the law itself, it is getting each individual psychiatrist authorized to prescribe. Before treating anyone, a psychiatrist has to get their own treatment protocol approved by a Human Research Ethics Committee, and that review alone can take months. Until that clears, the psychiatrist cannot prescribe at all, no matter how many patients are waiting. The legal pathway is arguably the most durable on this list. The patient pipeline is still thin.
Bottleneck: each psychiatrist needs months-long ethics committee approval before prescribing to anyone.
Fast access: 5/10.
Time to revenue: 7/10.
New Zealand
For now, New Zealand's entire psilocybin program runs through one doctor. In June 2025, regulators gave a single psychiatrist permission to prescribe psilocybin for treatment resistant depression, the first prescription outside a research trial in the country's history. A month later, guidance came out inviting other psychiatrists to apply, copying the Australian playbook closely enough that officials openly compared the two. But the applications take time to process, and right now, if you want legal psilocybin therapy in New Zealand, there is essentially one door to knock on. MDMA has no pathway at all yet. Worth watching closely. Not yet worth flying in for.
Bottleneck: only one authorized prescriber exists while the application pipeline for others is still being built.
Fast access: 2/10.
Time to revenue: 2/10.
“If you need patients this year, look at Switzerland. If you are betting on the next five years, look at Australia.”
Israel
Israel was the first national government anywhere to formally approve MDMA assisted therapy for patients outside a clinical trial, doing so in 2019 through a compassionate use program for PTSD. The program is capped at a small number of patients and limited to PTSD, with no equivalent pathway for psilocybin or depression. It proved the model works and helped pull other countries forward, but as a standalone market today it is narrow, both in scope and in patient ceiling.
Bottleneck: the program caps total patient numbers and covers PTSD only, with no psilocybin or depression pathway.
Fast access: 3/10.
Time to revenue: 3/10.
Germany
Germany is the newest entrant worth watching. In July 2025 it became the first EU country to approve compassionate access to psilocybin for treatment resistant depression. The mechanism is lighter than Switzerland's: psychiatrists at the two approved clinics, the Central Institute of Mental Health in Mannheim and OVID Clinic Berlin, decide which patients qualify themselves, without going back to a federal regulator for sign-off on each case. Treatment costs are covered by health insurance and the drug is provided free of charge, which removes the billing problem Switzerland leaves operators to solve on their own. The catch is capacity. Two clinics for an entire country, and demand is already expected to far exceed what those two sites can handle. MDMA is not covered.
Bottleneck: only two clinics are authorized nationally, and demand is already expected to outstrip capacity.
Fast access: 4/10.
Time to revenue: 5/10.
Canada
Canada added psilocybin and MDMA to its Special Access Program in 2022. Some clinics already operate this way, but the practitioner has to submit each request to Health Canada, the federal regulator, who reviews and approves or denies it individually. That makes Canada closer in structure to Switzerland than to Australia, every patient needs sign-off from the federal regulator itself, rather than a psychiatrist clearing one protocol review and then treating freely. There is no standardized intake like Switzerland or Australia have built, and approval rates have reportedly dropped between 2022 and 2024. Expect a slower, less predictable path in.
Bottleneck: every patient needs individual federal sign-off, with no standardized process and falling approval rates.
Fast access: 4/10.
Time to revenue: 4/10.
United States
The US remains the hardest market, and the largest. MDMA and psilocybin are still Schedule I federally. Real access needs FDA approval of an actual drug followed by DEA rescheduling, and neither has happened yet. Outside of one small expanded access program for around 50 patients in 2019, no compassionate use route exists. This is a multi year runway, not a multi month one, but the eventual market dwarfs everything else on this list.
Bottleneck: no medical pathway exists outside one small, closed 2019 program until FDA approval and DEA rescheduling both happen.
Fast access: 1/10.
Time to revenue: 1/10.
The wellness alternative
The Netherlands and Jamaica deserve a mention but do not belong in the ranking above. Psilocybin is fully legal in both, no prescriber or protocol required. But neither permits treating PTSD or depression as a medical condition. Frame it that way and you are operating outside the law that makes the access possible in the first place. These are real, profitable businesses, just not the same business as the seven markets above.
Bottleneck: the legal carve-out only works for personal or wellness use, not for treating a diagnosed medical condition.
Fast access: 10/10.
Time to revenue: 3/10.
The trade-off
Put the medical pathways side by side and the picture is this. Switzerland offers the most patients treated today, on a mechanism that stays case by case. Australia and New Zealand offer the cleanest law, with volume still catching up, New Zealand earlier in that process than Australia. Israel proved the concept but stayed narrow. Germany and Canada are live but smaller and less predictable. The US is the long game with the biggest eventual prize. If you need patients this year, look at Switzerland. If you are betting on the next five years, look at Australia.